PRA Health Sciences
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Revenues | 2.3b | 2.9b | 3.1b | 3.2b | 3.6b | 4.0b |
% growth | - | 27 % | 7 % | 4 % | 15 % | 9 % |
EBITDA | 339m | 429m | 482m | 416m | 615m | 690m |
% EBITDA margin | 15 % | 15 % | 16 % | 13 % | 17 % | 17 % |
Profit | 86.0m | 154m | 243m | 197m | 248m | 310m |
% profit margin | 4 % | 5 % | 8 % | 6 % | 7 % | 8 % |
EV / revenue | 2.5x | 2.1x | 2.7x | 2.8x | - | - |
EV / EBITDA | 17.0x | 13.9x | 17.1x | 21.7x | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | $3.0k | Grant | |
$12.0b Valuation: $12.0b 3.8x EV/LTM Revenues 28.8x EV/LTM EBITDA | Acquisition | ||
Total Funding | €2.7k |
Related Content
Recent News about PRA Health Sciences
EditPRA Health Sciences is a global healthcare intelligence partner specializing in clinical trial management and drug development. The company serves pharmaceutical and biotechnology firms, providing end-to-end support for clinical trials, from initial concept to final approval. Operating in the highly regulated healthcare market, PRA leverages its extensive expertise in recruitment, retention, and compliance to ensure rapid and efficient trial enrollment. The business model revolves around offering specialized services through its Centers of Expertise, which focus on areas such as vaccine research, pediatric clinical development, and immuno-oncology. PRA generates revenue by partnering with clients to design, manage, and execute clinical trials, thereby accelerating the path to market for new treatments. The company is consistently ranked among the top Contract Research Organizations (CROs) and is known for its people-first culture, emphasizing value, respect, and support for its employees.
Keywords: clinical trials, drug development, healthcare intelligence, pharmaceutical, biotechnology, recruitment, compliance, immuno-oncology, pediatric trials, global infrastructure.